Tagged with M

AMCHAM Malaysia Would you give our readers an insight into the government’s attempts to foster a better environment for FDI in Malaysia? Over the last year, the significant development has been the emergence of the Economic Transformation Programme (ETP). Through this initiative Malaysia is attempting to catapult itself out of the ‘middle-income…

PharmaExpert What is PharmaExpert’s role in the Polish pharmaceutical industry? The information that PharmaExpert gathers enables us to give good insight about the evolution of the pharmacists market, the evolution of the prices in the pharma landscape, and of the level of reimbursement, among others. PharmaExpert created a model of explanation…

Merck Sp. z.o.o You joined Merck in September 1996, took gradually increasing positions at Merck, from Medical Representative (1996 – 1998), to Sales and Marketing managing positions and you were ultimately appointed Managing Director Poland in January 2008. What have been the major challenges you faced in almost three years now? Merck in…

Novo Nordisk Pharma Sp. z.o.o Apart from Poland being a 40 million population market, with double digit growth, Mr. Kuczynski of Pierre Fabre was telling us that the main opportunity of the Polish market lies in the many unmet, local medical needs. What are the main specificities of the Polish market in your view and…

Bayer Co. Malaysia / Bayer Healthcare Malaysi Can you give our readers an outline of Bayer’s background in Malaysia and its current organisational division? Herbert Dittmar (HD): Bayer has been in Malaysia for around fifty years. It established its first legal entity here in the early 1970s and then engaged in a number of acquisitions worldwide including…

Malaysian Biotech Organisation (MBIO) Kebangsaan Malaysia (UKM). Singapore and Taiwan are known for their high level of basic research and their focus on Biotechnology. Philip Yeo, Chairman of Spring Singapore told us that Biomedical science was an undisputed pillar of Singapore’s economy. How do you situate Malaysia in terms of R&D compared to other…

Nycomed UK Ltd. Servier was eligible to receive $7 million in P3 funding; can you tell us how this initiative has helped the company? P3 was not one of the main reasons why Servier has invested more in Australia of late. What drives Servier’s headquarters to conduct more research in Australia is a…

Cegedim Strategic Data Malaysia Nowadays we can talk of an abundance of information coming from companies like Frost& Sullivan, IMS and even consultancies who are producing their own data. As a leader in market research how can CSD find a space within this picture and what strategies does it employ to stay ahead of…

Top Institute Pharma There is a very interesting history behind the origins of Top Institute Pharma (TI Pharma) as it aligned the interests of both the World Health Organization (Priority Medicines) and the EU’s Lisbon Strategy. Lisbon’s goal in 2000 was to transform the EU into the most powerful knowledge economy by 2010…

Lundbeck Limited (UK) If we look at Lundbeck globally, the company has been doing very well. Last year was a record year for profits. From a UK perspective, can you provide an overview of how you have seen the company performing since you arrived in 2009, and what your outlook is for 2011?…

Vifor Pharma UK Ltd You joined Vifor Pharma to establish a new structure in the UK. It is quite difficult to set up a new enterprise—what have been the main challenges for yourself and the organization in the year since Vifor Pharma UK came into being? I was actually the first employee of Vifor…

Lundbeck Malaysia You have worked in the pharmaceutical industry for many years starting with Novartis and you have spent the last eight years working for Lundbeck. What are the major changes that you have observed in the Malaysian pharmaceutical industry over that time? The industry’s approach has changed in its dealing with…